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Abstract 
 
    Traditional medicines have become the most productive source of leads for drugs development, particularly as 
anti-cancer agents. Various screening approaches are being applied. Sorafenib, a multikinase inhibitor, is used to treat 
primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer. A small library of compounds 
analogous to sorafenib were designed and screened for the treatment of liver cancer.  Multiple members of the family in an 
assay panel of tyrosine kinase family and serine/threonine-protein kinase family, including VEGFR, Abl, Aurora A, p 38, 
Lck, Src, PDGFR, Flt3, c-RAF, c-KIT, MEK(MAPKK) were selected to test these compounds. Analysis of the selectivity 
patterns for these compounds shows specificity for many kinase families. IC50 were measured for the selected compounds. 
Multiple compounds have very similar kinase inhibition profiles of VEGFR, Flt3, FGFR to that of sorafenib. The IC50 of 
c-RAF of BB1 is lower than sorafenib. The IC50 of c-RAF of BB3-12 is higher than that of sorafenib. For Flt3, IC50 of BB1-4 
is less than sorafenib. The IC50 value of KDR of BB1-10 is less than sorafenib. especially against c-RAF, PDGFR, c-KIT, 
KDR compared to sorafenib. These compounds are potent Raf1 and Flt4 kinase inhibitors. 
 
Key words: Tyrosine kinase inhibitors; Serine/threonine-protein kinase inhibitors; Sorafenib; Clinical hepatotoxicity. 
 
 
Introduction 
 
        Traditional medicines have become the most productive source of leads for drugs development, particularly 
as anti-cancer agents. Combinatorial chemistry approaches are being based on the scaffolds of traditional and alternative 
medicines to create screening libraries that closely resemble drug-like compounds. Various screening approaches are being 
developed and data mining and virtual screening techniques are being applied. At the present time, sorafenib approved by the 
FDA in 2005, is a multikinase inhibitor, targeting several serine/threonine and receptor tyrosine kinases (RAF kinase, 
VEGFR-2,VEGFR-3, PDGFR-beta, KIT, and FLT-3)(Hu et al., 2011). Sorafenib, is used to treat primary kidney cancer 
(advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). At the onset of the medicinal 
chemistry programme that led to sorafenib, there were no marketed kinase inhibitors in the field of oncology. However, 
before the approval of sorafenib, two first-generation targeted anticancer agents —Gleevec (Novartis) and Tarceva 
(Genentech), which target Bcr–Abl and EGFR, respectively — had begun to show clinical benefit (Capdeville et al., 2002), 
(Dowell et al., 2005) In multiple clinical trials, sorafenib is as both combination and single-agent therapies. 
        Analysis of newly introduced drugs states that sorafenib has reached the market from an origin in 
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high-throughput screening of combinatorial chemistry libraries. Tyrosine kinase inhibitor was discontinued from clinical 
development due to unexpected hepatotoxicity in cancer patients (Feng et al., 2009). Some drug has clinical toxicity and 
exerted its hepatotoxicity via both hepatocellular injury and hepatobiliary cholestatic mechanisms. The direct cytotoxic effect, 
hepatobiliary disposition and inhibition of active canalicular transport of bile constituents have been evaluated in established 
human hepatocyte models and in vitro transporter systems. The major human hepatic uptake transporter, multidrug resistance 
protein 1 (MDR1) and breast cancer resistance protein, was involved in hepatobiliary clearance. Evidence suggests three 
major mechanisms of medicine used clinically for the treatment of cholestatic liver diseases: (1) protection of cholangiocytes 
against cytotoxicity of hydrophobic bile acids, resulting from modulation of the composition of mixed phospholipid-rich 
micelles, reduction of bile acid cytotoxicity of bile and, possibly, decrease of the concentration of hydrophobic bile acids in 
the cholangiocytes; (2) stimulation of hepatobiliary secretion, putatively via Ca(2+) and protein kinase C-alpha-dependent 
mechanisms and/or activation of p38(MAPK) and extracellular signal-regulated kinases (Erk) resulting in insertion of 
transporter molecules (e.g., bile salt export pump, BSEP, and conjugate export pump, MRP2) into the canalicular membrane 
of the hepatocyte and, possibly, activation of inserted carriers; (3) protection of hepatocytes against bile acid-induced 
apoptosis, involving inhibition of mitochondrial membrane permeability transition (MMPT), and possibly, stimulation of a 
survival pathway. But effects on disease progression have not been further evaluated at the molecular level (Paumgartner and 
Beuers, 2002). 
        Tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell (Stepanek et al., 
2011). It functions as an "on" or "off" switch in many cellular functions. Receptor tyrosine kinases (RTK) are the 
high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Of the 90 unique tyrosine 
kinase genes identified in the human genome, 58 encode receptor tyrosine kinase proteins.(Robinson et al., 2000) This gene 
encodes a member of the Ser/Thr protein kinase family. This kinase is regulated through direct phosphorylation by p38 MAP 
kinase. In conjunction with p38 MAP kinase, this kinase is known to be involved in many cellular processes including stress 
and inflammatory responses. The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase. 
Serine/threonine-protein kinases select specific residues to phosphorylate on the basis of residues that flank the 
phosphoacceptor site, which together comprise the consensus sequence. Aurora A kinase known as serine/threonine-protein 
kinase 6 is an enzyme that in humans is encoded by the AURKA gene.  
 
Methods 
 
        We have recently disclosed a novel series of compounds as inhibitors of tyrosine kinases serine/threonine-protein 
kinases based on the source of traditional medicines. A minimized binding mode of the ATP pocket of the ligand-binding 
Pocket model is shown in Figure 1. A limited set of small hydrophobic groups may be substituted on this phenyl ring at very 
specific positions since the pocket possesses a limited tolerance for larger groups (Figure 1). The sketch of the components of 
the library and synthesis scheme is shown in Figure 2. 
    Based on the scaffold from nature products, we synthesized 50 compounds with the R1, R2 resion sit for the 
pocket. A small library of compounds analogous to sorafenib were designed and screened against multiple members of the 
tyrosine kinase and serine/threonine-protein kinase. To determine the kinase profiler and IC50 profiler, the reference inhibitor 
control compounds have been introduced in the kinase profiler and IC50 profiler express operational procedure. The structure 
of the tested compounds is shown in Table 1. Some tyrosine kinase and serine/threonine-protein kinase were selected to test 
the kinase profiler and IC50 (Table 2). 
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Figure 1:   Ligand-binding Pocket model 
Note: Green refers to sorafenib; Yellow refers to gleevec; Blue refers to tarceva. 
 
 
 
Figure 2: Sketch of the components of the library and the end products 
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Table 1: The structure of the tested compounds 
HN O
R2
OR1
HN
 
Compounds R1 R2 
BB1 1-Br-4-MePh 1H-imidazole 
BB2 1-Cl-4-MePh  Morpholin-4-amine 
BB3 1-F-4-MePh  Morpholinomethyl 4-methylbenzenesul 
BB4 5-methylisoxazole 2-morpholinoethyl 4-methylbenzenesulfonate 
BB5 2-methylnaphthalene 4-methoxybenzenamine 
BB6 p-xylene 4-chloropyridine 
BB7 3-methylisoxazol-5-amine 3-chloropyridine 
BB8 3-methylisoxazole N,4-dimethylpicolinamide 
BB9 toluene 2-Cl-5-nitropyridine 
BB10 4-chloropyridine N-(3-aminopyridin-2-yl)acetamide 
BB11 1-methoxy-3-methylbenzene Pyrimidine-4,5-diamine 
BB12 1-fluoro-2-methyl-4-(trifluoromethyl)ben
zene 
4,6-dichloropyrimidin-5-amine 
 
Table 2: Selected kinases 
Family Kinase Full name 
c-Kit (CD117) tyrosine-protein kinase Kit or 
Flt3 (CD 135) fms-like tyrosine kinase receptor-3  
RTKs (VEGFR) Receptor tyrosine kinases ( vascular 
endothelial growth factor receptors ) 
RTKs (FGFR1) fibroblast growth factor receptor 1 
RTKs (EGFR) epidermal growth factor receptor 
RTKs(PDGFRα, PDGFRβ) Platelet-derived growth factor receptor 
Abl V-abl Abelson murine leukemia viral 
oncogene homolog 
Lck lymphocyte-specific protein tyrosine 
kinase 
Src proto-oncogenic tyrosine kinase 
Tyrosine kinase 
 
KDR type III receptor tyrosine kinase (vascular 
endothelial growth factor receptor 2) 
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p38 (SAPK2a) mitogen-activated protein (MAP) 
kinase-activated protein kinase 2 
MEK(MAPKK) MAP kinase cascade 
c-RAF  RAF proto-oncogene 
serine/threonine-protein kinase 
Aurora-A  serine/threonine-protein kinase 6 
Serine/threonine-protein 
kinase 
CDK2/cyclinA Cyclin-dependent kinase 2 
 
 
Kinase Profiler and IC50 Profiler  
 
    A family of validated kinase targets was identified with specific structural features. The composition of the 
dilution buffer for each kinase is shown in Table 3. All kinases are pre-diluted to a 10x working concentration prior to 
addition into the assay. The Kinase Profiler of ATP concentration is shown in Table 4. 
 
Table 3. Buffer composition of kinase dilution 
Buffer composition Kinase (s) 
50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4,  c-Kit  
0.1% β-mercaptoethanol,  c-RAF  
1 mg/ml BSA  Flt3  
50 mM Tris pH 7.5, 0.1 mM EGTA,  PDGFRα  
0.1% β-mercaptoethanol, 1 mg/ml BSA  SAPK2a  
50 mM Tris pH 7.5, 0.05% β-mercaptoethanol,  RTKs (VEGFR) 
1 mg/ml BSA  EGFR 
25 mM Tris pH 7.5, 0.1 mM EGTA,  FGFR1 
0.1% β-mercaptoethanol, 1 mg/ml BSA  MEK1 
20 mM MOPS pH 7.0, 1 mM EDTA,  Abl 
0.1% β-mercaptoethanol, 0.01% Brij-35,  Aurora-A  
5% glycerol, 1 mg/ml BSA  CDK2/cyclinA 
20 mM HEPES pH 7.6, 0.15 M NaCl,  Lck 
0.1 mM EGTA, 5 mM DTT, 0.1% Triton X-100,  p38 
50% glycerol  MAPKAP-K3 
180 mM HEPES pH 7.4, 3.6 mM DTT,  PDGFRα  
0.07% Brij-35  PDGFRβ 
40 mM HEPES pH 7.4, 1 mg/ml BSA   
20 mM HEPES pH 7.4, 0.03% Triton X-100   
50 mM Na β-glycerophosphate pH 7.0, 0.1%   
β-mercaptoethanol, 0.1 mM EGTA, 1 mg/ml BSA    
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Table 4:  Kinase Profiler of ATP concentration 
Kinase    Km Assay Conc   
Abl   45μM 
Abl(T315I)    10μM   
Aurora-A     15μM   
c-Kit    200μM   
c-RAF    45μM   
CDK2/cyclinA    45μM   
EGFR    10μM   
 
 
 
IC50 was measured for the selected compounds with the best activities below 50 nM in Upstate BioPredict Inc. Each protein 
kinase has been paired with an ATP-competitive inhibitor that is included on every assay plate as a reference blank.  
Abl  
In a final reaction volume of 25 μl, Abl (m) (5-10 mU) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 μM 
EAIYAAPFAKKK, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as 
required).The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, 
the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the reaction is then spotted onto a 
P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in meth\anol prior to drying and 
scintillation counting. 
c-KIT  
In a final reaction volume of 25 μl, c-KIT   (5-10 mU) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM 
MnCl2, 0.1 mg/ml poly(Glu, Tyr) 4:1, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, 
concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at 
room temperature, the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the reaction is 
then spotted onto a Filtermat A and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior 
to drying and scintillation counting. 
Lck   
In a final reaction volume of 25 μl, Lck (5-10 mU) is incubated with 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 
250 μM KVEKIGEGTYGVVYK (Cdc2 peptide), 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 
cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 
minutes at room temperature, the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the 
reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in 
methanol prior to drying and scintillation counting. 
MEK1   
In a final reaction volume of 25 μl, MEK1 (1-5 mU) is incubated with 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% 
β-mercaptoethanol, 0.01% Brij-35, 1 μM inactive MAPK2 (m), 10 mM MgAcetate and cold ATP (concentration as required). 
The reaction is initiated by the addition of the MgATP. After incubation for 40 minutes at room temperature, 5 μl of this 
incubation mix is used to initiate a MAPK2 (m) assay, which is described on page 12 of this book. 
PDGFR 
In a final reaction volume of 25 μl, PDGFRα (5-10 mU) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1 mg/ml 
poly (Glu, Tyr) 4:1, 10 mM MnCl2, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, 
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concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at 
room temperature, the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the reaction is 
then spotted onto a filtermat A and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to 
drying and scintillation counting. 
SAPK2a   
In a final reaction volume of 25 μl, SAPK2a (5-10 mU) is incubated with 25 mM Tris pH 7.5, 0.02 mM EGTA, 0.33 mg/ml 
myelin basic protein, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as 
required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, 
the reaction is stopped by the addition of 5 μl of a 3% phosphoric acid solution. 10 μl of the reaction is then spotted onto a 
P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and 
scintillation counting. 
 
Results 
 
    A small library of compounds analogous to sorafenib were designed and screened against multiple members of the 
family at Millipore-Upstate BioPredict Inc in an assay panel. Analysis of the selectivity patterns for these compounds shows 
specificity for many kinase families. IC50 were measured for the selected compounds. The potentially comprise an alternative 
group of compounds that are highly interesting, as for Flt3 and KDR, IC50 of BB1, BB2, BB3, BB4 is less than sorafenib. To 
assess the potential of these compounds to inhibit kinases, we screened the compounds at Upstate BioPredict Inc. The tested 
compounds were also shown to potently inhibit the wild-type kinases including KDR, FGFR1 and other RTKs involved in 
tumorigenesis (c-Kit, Flt-3 and RET) in vitro. Figure 2 shows the comparison between the IC50 values determined by 
functional assays for different kinases. In these kinases, the IC50 values of VEGFR, Flt3, FGFR is similar to sorafenib. Some 
compounds show difference, especially against c-RAF, PDGFR, c-KIT, KDR compared to sorafenib. The IC50 of c-RAF of 
BB1(2μM) is lower than that of sorafenib (6μM). The IC50 of c-RAF of BB3(85μM),BB4(91μM), BB5(97μM), BB6(105μM), 
BB7(91μM), BB8(101μM), BB9(50μM), BB10(79μM), BB11(85μM) and BB12(94μM) is higher than that of 
sorafenib(6μM). The IC50 value of Flt3 of BB1 (1μM), BB2(4μM), BB3(3μM) and BB4(5μM) is less than sorafenib (58μM). 
The IC50 value of KDR of BB1(4μM), BB2(4μM),BB3(4μM), BB4(3μM), BB5(25μM), BB6(8μM), BB7(22μM), 
BB8(11μM), BB9(69μM) and BB10(7μM) is less than sorafenib (90μM).  These results of the multiple compounds have 
very similar kinase inhibition profile to that of sorafenib. In vitro assays confirmed that these compounds (compound BB71A 
and compound 28) are potent in vitro inhibitor of Raf1 kinase and Flt4 (IC50 of 2 nM and 1 nM) (Figure 2). However, similar 
to sorafenib, these compounds had no significant inhibitory effect on PKCγ, PKA, PKCα, MEK1, Met, IGF-1R. 
 
Discussion 
 
        Some anti-tumor agent contained in traditional Chinese medicine, has been extensively used, such as quercetin, 
baicalein, baicalin, salvianolic acid B and emodin. In the present study, we investigated the selectivity patterns for the 
compounds which showed specificity for tyrosine kinase and serine/threonine-protein kinase families. IC50 were measured 
for the selected compounds (Gao et al., 2011). Clinical cases reported that fatal acute liver failure occurred when paracetamol 
(acetaminophen) was co-administrated with some tyrosine kinase inhibitors. The direct inhibition of 
UDP-glucuronosyltransferase activities has been identified as a mechanism of potentiation of paracetamol hepatotoxicity 
(Liu et al., 2011). Some tyrosine kinase inhibitors have increased propensity to cause hepatotoxicity, which may be fatal in 
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Figure 3:  Kinase analysis profile of some compounds 
Note: Each cell represents a compound (the structure of compound is shown in Table 1), with numbers as the residual 
activities of each kinase in the presence of 5 μM individual compound. Green color means great inhibition; Black color 
means 50% inhibition; Red color means worse inhibition. 
 
 
rare cases (Keisner and Shah, 2011). The Raf serine/threonine kinase isoforms (A-Raf, B-Raf and Raf) are the first kinases in 
the MAPK cascade and are pivotal regulators of cellular proliferation and survival (Pruitt et al., 2002). McDonald et al. 
(McDonald et al., 1999) had developed an approach for the high-throughput screening (HTS) and identification of selective 
Raf/MEK/ERK enzyme inhibitors using tumour cell lines that contained oncogenic k-ras and/or b-raf mutations 
demonstrated upregulated signalling through the Raf–MEK–ERK pathway. We designed and analysed multiple compounds 
that have very similar kinase inhibition profiles of VEGFR, Flt3, FGFR to that of sorafenib. Some compounds, especially 
against c-RAF, PDGFR, c-KIT, KDR compared to sorafenib. The IC50 of c-RAF of BB1(2μM) is lower than that of sorafenib 
(6μM). The IC50 of c-RAF of BB3(85μM),BB4(91μM), BB5(97μM), BB6(105μM), BB7(91μM), BB8(101μM), BB9(50μM), 
BB10(79μM), BB11(85μM) and BB12(94μM) is higher than that of sorafenib(6μM). The IC50 value of Flt3 of BB1 (1μM), 
BB2(4μM), BB3(3μM) and BB4(5μM) is less than sorafenib (58μM). The IC50 value of KDR of BB1(4μM), 
BB2(4μM),BB3(4μM), BB4(3μM), BB5(25μM), BB6(8μM), BB7(22μM), BB8(11μM), BB9(69μM) and BB10(7μM) is less 
than sorafenib (90μM). 
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